$3.02
4.97%
Downside
Day's Volatility :17.77%
Upside
13.47%
9.6%
Downside
52 Weeks Volatility :74.0%
Upside
71.23%
Period | Galmed Pharmaceuticals Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -25.98% | 0.0% |
6 Months | -33.77% | 0.0% |
1 Year | -68.84% | 0.0% |
3 Years | -99.47% | -22.3% |
Market Capitalization | 2.0M |
Book Value | $22.24 |
Earnings Per Share (EPS) | -10.44 |
PEG Ratio | 0.0 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -29.31% |
Return On Equity TTM | -52.67% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -6.1M |
Diluted Eps TTM | -10.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 297.35%
Sell
Neutral
Buy
Galmed Pharmaceuticals Ltd is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Galmed Pharmaceuticals Ltd | -11.07% | -33.77% | -68.84% | -99.47% | -99.66% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Galmed Pharmaceuticals Ltd | NA | NA | 0.0 | 0.0 | -0.53 | -0.29 | NA | 22.24 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Galmed Pharmaceuticals Ltd | Buy | $2.0M | -99.66% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Galmed Pharmaceuticals Ltd
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 105.9%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 168.7%
CVI Holdings LLC
Walleye Trading Advisors, LLC
Morgan Stanley - Brokerage Accounts
TWO SIGMA SECURITIES, LLC
UBS Group AG
galmed pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or fabacs. aramchol is initially being developed for treating non-alcoholic steato-hepatitis, or nash, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. galmed pharmaceuticals galmed’s business has been, in its current legal structure, was incorporated in israel on july 31, 2013 as a privately held company. however, operating since 2000 under a different group of companies established in the same year. galmed was co-founded by professor tuvia gilat and allen baharaff, based on professor gilat’s extensive research in fabac’s and nash.
Organization | Galmed Pharmaceuticals Ltd |
Employees | 3 |
CEO | Mr. Allen Baharaff |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.02
-11.8%
Keyarch Acquisition Corp
$3.02
-11.8%
Connexa Sports Technologies Inc
$3.02
-11.8%
Us Value Etf
$3.02
-11.8%
First Wave Biopharma Inc
$3.02
-11.8%
Global X Msci Next Emerging
$3.02
-11.8%
Fat Projects Acquisition Corp
$3.02
-11.8%
Capital Link Global Fintech
$3.02
-11.8%
Applied Uv Inc
$3.02
-11.8%